Schonfeld Strategic Advisors’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Schonfeld Strategic Advisors’s Portfolio HARP Stock Details HARP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-24,022	Closed	-$458K	–	3282
2022 Q2	$458K	Buy	24,022 +2,156	+10%	+$55.8K	﹤0.01%	1414
2022 Q1	$1.09M	Buy	21,866 +12,907	+144%	+$669K	0.01%	949
2021 Q4	$676K	Buy	8,959 +532	+6%	+$36.3K	0.01%	1122
2021 Q3	$666K	Buy	8,427 +2,455	+41%	+$247K	0.01%	1135
2021 Q2	$828K	Sell	5,972 -198	-3%	-$37.8K	0.01%	995
2021 Q1	$1.29M	Buy	+6,170	New	+$1.24M	0.02%	797

Other funds holding HARP

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PSC

Piper Sandler & Co Minneapolis, Minnesota $135M AUM 0.15% 1-Year Est. Return

Schonfeld Strategic Advisors's HARP Position: Q3 2022 in Review

Schonfeld Strategic Advisors sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q3 2022, closing a stake of 24,022 shares — an estimated $458K sold.

Schonfeld Strategic Advisors first reported a position in HARP in Q1 2021 and held it in 6 quarters. The position peaked at $1.29M in Q1 2021. 52 funds tracked by Wall St. Rank hold HARP as of Q3 2022.

Schonfeld Strategic Advisors reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Schonfeld Strategic Advisors sold 24,022 Harpoon Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $458K.
Schonfeld Strategic Advisors first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q1 2021 and held it in 6 quarters.
Schonfeld Strategic Advisors's Harpoon Therapeutics, Inc. Common Stock position peaked at $1.29M in Q1 2021.
52 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.